Anti-MLH1 抗体 (Agarose) (ab1295)


  • 製品名Anti-MLH1 antibody (Agarose)
    MLH1 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to MLH1 (Agarose)
  • 標識Agarose
  • アプリケーション適用あり: IPmore details
  • 種交差性
    交差種: Human
    交差が予測される動物種: Mouse
  • 免疫原

    Synthetic peptide (Human) conjugated to KLH - which represents a portion of human Homolog 1 of E. coli MutL Protein encoded within exon 20 (LocusLink ID 4292).

  • 特記事項

    Affinity purified antibodies were coupled to agarose beads using a cyanogen bromide method.



Our Abpromise guarantee covers the use of ab1295 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
  • 追加情報IP: Use at 15 to 25 µl of gel slurry per 0.1 to 1 mg of protein lysate or extract.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • ターゲット情報

    • 機能Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
    • 組織特異性Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
    • 関連疾患Defects in MLH1 are the cause of hereditary non-polyposis colorectal cancer type 2 (HNPCC2) [MIM:609310]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
      Defects in MLH1 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
      Defects in MLH1 are a cause of Muir-Torre syndrome (MuToS) [MIM:158320]; also abbreviated MTS. MuToS is a rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.
      Note=Defects in MLH1 may contribute to lobular carcinoma in situ (LCIS), a non-invasive neoplastic disease of the breast.
      Defects in MLH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:608089].
      Note=Some epigenetic changes can be transmitted unchanged through the germline (termed 'epigenetic inheritance'). Evidence that this mechanism occurs in humans is provided by the identification of individuals in whom 1 allele of the MLH1 gene is epigenetically silenced throughout the soma (implying a germline event). These individuals are affected by HNPCC but does not have identifiable mutations in MLH1, even though it is silenced, which demonstrates that an epimutation can phenocopy a genetic disease.
    • 配列類似性Belongs to the DNA mismatch repair mutL/hexB family.
    • 細胞内局在Nucleus.
    • Information by UniProt
    • 参照データベース
    • 別名
      • COCA 2 antibody
      • COCA2 antibody
      • DNA mismatch repair protein Mlh1 antibody
      • FCC 2 antibody
      • FCC2 antibody
      • hMLH 1 antibody
      • hMLH1 antibody
      • HNPCC 2 antibody
      • HNPCC antibody
      • HNPCC2 antibody
      • MGC5172 antibody
      • MLH 1 antibody
      • MLH1 antibody
      • MLH1_HUMAN antibody
      • MutL homolog 1 (E. coli) antibody
      • MutL homolog 1 antibody
      • MutL homolog 1 colon cancer nonpolyposis type 2 antibody
      • MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody
      • MutL protein homolog 1 antibody
      • MutL, E. coli, homolog of, 1 antibody
      see all

    Anti-MLH1 antibody (Agarose) (ab1295) 使用論文

    ab1295 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for your email. I understand that you are frustrated with these two antibodies. Abcam values all feedback from customers, both positive and negative. The quality of the products that we offer to our customers is very important to us, and beca...

    Read More

    The problem may be that the immobilized antibodies are not designed for regeneration. They are designed for a single time use with elution using SDS-PAGE sample buffer containing a reducing agent (e.g. BME). It is suggested that you should run a ge...

    Read More

    Thank you very much for your patience. I passed on your comments to the originator of ab1294 and ab1295. I agree that this is a problem, and appreciate your feedback regarding these antibodies. At this time I honestly don't know what is causing the pro...

    Read More

    Thank you for your patience. The originator of ab1294 and ab1295 was able to tell me that the specifications for the agarose beads used are - Agarose: 4% Exclusion limit: 20,000,000 Diameter: 60 to 160 um. If you have any more questions, please cont...

    Read More

    Within the peptide used for antibody production, there are no serine or threonine. There is one hydroxyl containing residue, which is tyrosine.

    The precise sequence of the peptide used for antibody production is proprietary. If you need to know the extent to which it is likely that this antibody will react with MLH1 from other species. Please provide the accession number for your protein.